After mixed reviews, Lilly’s experimental Alzheimer drug awaits reaction from Wall Street

Here’s the million-dollar question for Eli Lilly and Co. as today’s market opens: Did the drugmaker finally score a major breakthrough with its much-anticipated new treatment for Alzheimer’s disease? If so, the Indianapolis-based company could see its stock …

Read more at www.ibj.com